Medpace Holdings, Inc. (MEDP) Earnings Per Share (EPS): 15.92
Is Medpace Holdings, Inc.’s earnings per share (EPS) high or low?
Medpace Holdings, Inc.'s earnings per share (EPS) of 15.92 is 75% above its 5-year average of 9.10, near the high end of its 5-year range (4.07–15.92).
As of Wednesday, June 17, 2026. 10.94% above its 12-month average of 14.35.
MEDP Earnings Per Share (EPS) Chart
MEDP Average Earnings Per Share (EPS) Chart
MEDP Current vs Average Earnings Per Share (EPS) Chart
MEDP Earnings Per Share (EPS) Metrics
EARNINGS PER SHARE (EPS)
15.92
EARNINGS PER SHARE (EPS) AVG TTM
14.35
EARNINGS PER SHARE (EPS) AVG 3Y
11.37
EARNINGS PER SHARE (EPS) AVG 5Y
9.10
EARNINGS PER SHARE (EPS) AVG 10Y
5.50
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.94%
CURRENT VS 3Y AVG
+40.05%
CURRENT VS 5Y AVG
+74.95%
CURRENT VS 10Y AVG
+189.26%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' Earnings Per Share (EPS)
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.05B | 15.92 | 14.35 | 11.37 | 9.10 |
| The Cooper Companies, Inc. (COO)vs › | $13.14B | 1.18 | 1.92 | 1.82 | 11.98 |
| Solventum Corporation (SOLV)vs › | $12.91B | 8.17 | 5.85 | 6.82 | 7.06 |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 5.96 | 5.64 | 5.43 | 9.01 |
| DaVita Inc. (DVA)vs › | $13.46B | 9.94 | 10.37 | 8.56 | 8.35 |
| Revvity, Inc. (RVTY)vs › | $10.91B | 2.10 | 2.25 | 2.01 | 3.78 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -7.29 | -6.79 | -1.56 | -0.26 |
| Baxter International Inc. (BAX)vs › | $10.19B | -2.10 | -1.51 | -0.65 | 0.36 |
| Hologic, Inc. (HOLX)vs › | $16.97B | 2.40 | 2.92 | 3.22 | 4.07 |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | -3.76 | -1.35 | 4.03 | 5.21 |
EPS Comparison
Trailing EPS (TTM)
$15.92
Forward EPS (Est.)
$18.37
P/E Ratio
28.7
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
- Directly impacts stock valuation through P/E ratio
- Used to calculate dividend coverage and payout ratios
- Enables comparison across companies of different sizes
- Growth in EPS often correlates with stock price appreciation
Medpace Holdings, Inc. Earnings Per Share (EPS) Formula & Definition
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Earnings Per Share (EPS) FAQ
- What is the earnings per share (EPS) for Medpace Holdings, Inc. (MEDP)?
- The earnings per share (EPS) for MEDP stock is 15.92.
- Is Medpace Holdings, Inc.'s earnings per share (EPS) high or low?
- Medpace Holdings, Inc.'s earnings per share (EPS) of 15.92 is 75% above its 5-year average of 9.10, near the high end of its 5-year range (4.07–15.92).
- What is the TTM average earnings per share (EPS) for Medpace Holdings, Inc. (MEDP)?
- The TTM average earnings per share (EPS) for MEDP stock is 14.35.
- What is the 3Y average earnings per share (EPS) for Medpace Holdings, Inc. (MEDP)?
- The 3Y average earnings per share (EPS) for MEDP stock is 11.37.
- What is the 5Y average earnings per share (EPS) for Medpace Holdings, Inc. (MEDP)?
- The 5Y average earnings per share (EPS) for MEDP stock is 9.10.
- What is the 10Y average earnings per share (EPS) for Medpace Holdings, Inc. (MEDP)?
- The 10Y average earnings per share (EPS) for MEDP stock is 5.50.
Medpace Holdings, Inc. Earnings Per Share (EPS) History
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 15.64 |
| 2024-12-31 | 13.06 |
| 2023-12-31 | 9.20 |
| 2022-12-31 | 7.57 |
| 2021-12-31 | 5.06 |
| 2020-12-31 | 4.07 |
| 2019-12-31 | 2.79 |
| 2018-12-31 | 2.05 |
| 2017-12-31 | 1.00 |
| 2016-12-31 | 0.38 |
| 2015-12-31 | -0.28 |
| 2014-12-31 | -0.53 |
| 2013-12-31 | 1.33 |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle